577,228 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 577,228 shares of the biotechnology company's stock, valued at approximately $14,979,000. Caisse DE Depot ET Placement DU Quebec owned approximately 0.20% of Exelixis as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of EXEL. Hsbc Holdings PLC increased its holdings in shares of Exelixis by 45.3% in the second quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company's stock valued at $2,031,000 after purchasing an additional 28,126 shares during the period. Farallon Capital Management LLC grew its holdings in shares of Exelixis by 1.6% in the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company's stock worth $608,993,000 after acquiring an additional 424,000 shares during the period. Seizert Capital Partners LLC increased its stake in Exelixis by 8.0% in the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company's stock valued at $12,195,000 after purchasing an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock worth $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company's stock worth $1,424,000 after purchasing an additional 20,641 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Insider Buying and Selling

In other news, EVP Dana Aftab sold 1,162 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the sale, the executive vice president now directly owns 498,945 shares of the company's stock, valued at approximately $15,666,873. This represents a 0.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director George Poste sold 30,000 shares of the firm's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the transaction, the director now owns 169,020 shares in the company, valued at $5,746,680. This represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 339,736 shares of company stock valued at $11,508,610. Insiders own 2.85% of the company's stock.

Exelixis Trading Down 2.4 %

EXEL stock traded down $0.87 during midday trading on Monday, hitting $35.59. 2,048,262 shares of the company's stock were exchanged, compared to its average volume of 2,070,506. The stock has a market capitalization of $10.16 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 0.92 and a beta of 0.51. The firm has a 50 day moving average price of $30.82 and a 200-day moving average price of $26.15. Exelixis, Inc. has a 12-month low of $19.20 and a 12-month high of $36.97.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same period in the prior year, the company posted $0.10 EPS. The business's revenue was up 14.3% compared to the same quarter last year. On average, sell-side analysts forecast that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Stephens boosted their price objective on shares of Exelixis from $23.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 30th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $34.00 price target on shares of Exelixis in a research note on Wednesday, October 30th. HC Wainwright restated a "buy" rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. JMP Securities reiterated a "market outperform" rating and issued a $29.00 target price on shares of Exelixis in a research note on Friday, October 11th. Finally, Bank of America raised their price target on Exelixis from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.